Literature DB >> 12179991

Enantioseparation of novel COX-2 anti-inflammatory drugs by capillary electrophoresis using single and dual cyclodextrin systems.

Carmen Calvet1, Rosa Cuberes, Carlos Pérez-Maseda, Jordi Frigola.   

Abstract

A capillary electrophoresis method was developed for the enantioseparation of three novel cyclooxygenase-2 (COX-2) inhibitor drugs (E-6259, E-6036 and E-6087) with anti-inflammatory and analgesic activities using sulfobutyl ether-beta-cyclodextrin (SBE-beta-CD) as a chiral selector. The use of 50 mM sodium tetraborate at pH 9.2 with 30% v/v methanol, containing 7.1 mM SBE-beta-CD, as a background electrolyte (BGE) allowed the complete enantioseparation of the three neutral racemic mixtures (resolution = 2.4, 3.0 and 8.7, respectively) and their corresponding metabolites (oxidation products) in a single run. Migration times were shortened with some loss of enantioresolution by adding 1.75 mM dimethyl-beta-cyclodextrin (DM-beta-CD) to the previous BGE (dual CD system). The reversal of the migration order of E-6259 enantiomers in the dual CD system was also studied. Furthermore, the addition of DM-beta-CD to the BGE introduced a new chemoselectivity in the system that allowed E-6259 to be separated from the structurally similar compound E-6036.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12179991     DOI: 10.1002/1522-2683(200206)23:11<1702::AID-ELPS1702>3.0.CO;2-#

Source DB:  PubMed          Journal:  Electrophoresis        ISSN: 0173-0835            Impact factor:   3.535


  2 in total

1.  Comparative In vitro Metabolism of Enflicoxib in Dogs, Rats, and Humans: Main Metabolites and Proposed Metabolic Pathways.

Authors:  Josep Solà; Àngel Menargues; Josep Homedes; Marta Salichs; Maria Teresa Serafini; Gregorio Encina
Journal:  Drug Metab Lett       Date:  2021

2.  Selective inhibition of cyclooxygenase-2 by enflicoxib, its enantiomers and its main metabolites in vitro in canine blood.

Authors:  Josep Solà; Àngel Menargues; Josep Homedes; Marta Salichs; Inés Álvarez; Luz Romero; José Miguel Vela
Journal:  J Vet Pharmacol Ther       Date:  2022-01-17       Impact factor: 1.567

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.